A previous clinical study indicated that the lipid-lowering effect of FGF21 is more significant than that of hypoglycemia in humans 126, enlightening us to explore the potential of applying FGF21 with clinical antidiabetic drugs instead of applying FGF21 alone. The gene discussed is FGF21; the disease is Hypoglycemia.